TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) have earned an average recommendation of “Moderate Buy” from the six analysts that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $37.67.

Several analysts have issued reports on the stock. The Goldman Sachs Group increased their target price on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. HC Wainwright upped their price target on shares of TG Therapeutics from $49.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. B. Riley lifted their price objective on TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Finally, TD Cowen began coverage on TG Therapeutics in a research report on Tuesday, October 29th. They set a “buy” rating and a $50.00 target price for the company.

Insider Buying and Selling

In related news, Director Sagar Lonial sold 5,000 shares of the firm’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $30.44, for a total transaction of $152,200.00. Following the transaction, the director now directly owns 100,195 shares of the company’s stock, valued at approximately $3,049,935.80. This trade represents a 4.75 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. 10.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. State Street Corp lifted its holdings in shares of TG Therapeutics by 35.8% in the 3rd quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company’s stock worth $212,712,000 after acquiring an additional 2,398,015 shares during the last quarter. Marshall Wace LLP purchased a new position in TG Therapeutics in the 2nd quarter worth $36,501,000. Principal Financial Group Inc. lifted its stake in TG Therapeutics by 1,549.4% in the third quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company’s stock worth $18,061,000 after purchasing an additional 725,371 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in TG Therapeutics during the second quarter valued at about $10,423,000. Finally, Assenagon Asset Management S.A. purchased a new stake in TG Therapeutics during the second quarter valued at about $8,698,000. 58.58% of the stock is currently owned by institutional investors.

TG Therapeutics Stock Performance

NASDAQ:TGTX opened at $35.07 on Monday. TG Therapeutics has a 52-week low of $12.30 and a 52-week high of $36.50. The business’s fifty day moving average is $25.62 and its 200 day moving average is $21.70. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The firm has a market cap of $5.46 billion, a price-to-earnings ratio of -350.66 and a beta of 2.19.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The firm had revenue of $83.90 million during the quarter, compared to analysts’ expectations of $81.68 million. During the same period in the previous year, the company posted $0.73 earnings per share. The company’s quarterly revenue was down 49.4% compared to the same quarter last year. Research analysts predict that TG Therapeutics will post 0.17 EPS for the current year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.